Trial Profile
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs TV 5010 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 03 Apr 2022 Status changed from recruiting to completed.
- 14 Nov 2012 New trial record